Abstract
The present study examines the clinical significance of serum neuron-specific enolase (NSE) in patients with non-germinal center B-cell type (non-GCB) of diffuse large B-cell lymphoma (DLBCL) that received rituximab chemotherapy. Serum NSE values were measured using electrochemiluminescence assay in 53 patients. About 54.7% of the DLBCL patients had positive expression of serum NSE (>15.20 ng/ml), which closely correlated with performance status, serum LDH level, B symptoms, IPI scores, and Ann-Arbor stages (P < 0.05). The mean serum NSE value in patients with non-GCB subtype of DLBCL was significantly higher than that of GCB subtype of DLBCL (P = 0.001), and among patients in non-GCB subtype group, there was significant difference in the 5-year OS rate between NSE-positive group and negative group (28.3% vs. 81.6%, P < 0.001). Furthermore, serum NSE level was found to be an independent prognostic factor in patients with non-GCB subtype. Serum NSE may be a novel marker of disease aggressiveness as well as a prognostic factor for non-GCB subtype of DLBCL in the era of rituximab.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimes for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328:1002–6.
Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene. 2007;26:3603–13.
Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–11.
Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–82.
Xia ZG, Xu ZZ, Zhao WL, et al. The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment. Ann Hematol. 2010;89:171–7.
Fang C, Xu W, Li JY. A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma. Ann Hematol. 2010;89:1107–13.
Shizusawa T, Shibayama H, Murata S, et al. The expression of anamorsin in diffuse large B cell lymphoma: possible prognostic biomarker for low IPI patients. Leuk Lymphoma. 2008;49(1):113–21.
Tapia FJ, Polak JM, Barbosa AJ, et al. Neuron-specific enolase is produced by neuroendocrine tumours. Lancet. 1981;1:808–11.
Nakatsuka S, Nishiu M, Tomita Y, et al. Enhanced expression of neuron-specific enolase (NSE) in pyothorax-associated lymphoma (PAL). Jpn J Cancer Res. 2002;93:411–6.
Delsol G. The 2008 WHO lymphoma classification. Ann Pathol. 2008;28(Spec No 1):S20–4.
Miller AA, Salewski E. Prospects for pirarubicin. Med Pediatr Oncol. 1994;22:261–8.
Tsurumi H, Yamada T, Sawada M, et al. Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin’s lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol. 2004;130:107–13.
Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.
Li JM, Wang L, Shen Y, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients. Ann Hematol. 2007;86:639–45.
Berglund M, Thunberg U, Amini RM, et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol. 2005;18:1113–20.
Shiozawa E, Yamochi-Onizuka T, Takimoto M, Ota H. The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries. Leuk Res. 2007;31:1579–83.
Nemeth J, Galian A, Mikol J. Béatrix Cochand-Priollet, Michel Wassef and Anne Lavergne. Neuron-specific enolase and malignant lymphomas (23 cases). Virchows Arch A Pathol Anat Histopathol. 1987;412:89–93.
Moro MA, De Alba J, Cardenas A, et al. Mechanisms of the neuroprotective effect of aspirin after oxygen and glucose derivation in rat forebrain slices. Neuropharmacology. 2000;39:1309–18.
Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194(12):1861–74.
Fujiwara H, Arima N, Ohtsubo H, et al. Clinical significance of serum neuron-specific enolase in patients with adult T-cell leukemia. Am J Hematol. 2002;71:80–4.
Acknowledgments
Our work was supported by the following funds: National Natural Science Foundation of China, and the contract/grant number is 30471976; Science and technology projects of Guangdong Province, and the contract/grant number is 2010B031600233 and 2010A090200019.
Conflict of interest
The authors report no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, L., Liu, P., Chen, X. et al. Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center B cell-like subtype of diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy. Med Oncol 29, 2153–2158 (2012). https://doi.org/10.1007/s12032-011-0049-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-011-0049-z